ULCERATIVE COLITIS TREATMENTS | ||||
---|---|---|---|---|
Generic | Brand | Strength | Form | Dose |
AMINOSALICYLATE | ||||
balsalazide disodium | Colazal | 750mg | caps | Adults: Treatment: 2.25g 3 times daily for 8wks; max 12wks. Children: <5yrs: not recommended. ≥5yrs: Treatment: 2.25g 3 times daily or 750mg 3 times daily; max 8wks. |
mesalamine | Apriso | 0.375g | ext-rel caps | ≥18yrs: Maintenance: 1.5g once daily in the AM. <18yrs: Not recommended. |
Asacol HD | 800mg | del-rel tabs | Adults: Treatment: 1600mg 3 times daily for 6wks. Children: Not recommended. |
|
Canasa | 1g | supp | Adults: Treatment: 1g once daily at bedtime for 3−6wks. Retain supp in rectum for at least 1−3hrs. Children: Not established. |
|
Delzicol | 400mg | del-rel caps | Adults: Treatment: 800mg 3 times daily for 6wks. Maintenance: 1.6g daily in 2−4 divided doses. Children: <5yrs: not established. ≥5yrs (17–32kg): 36−71mg/kg/day, max 1.2g/day; (33–53kg): 37−61mg/kg/day, max 2g/day; (54−90kg): 27−44mg/kg/day, max 2.4g/day; give in 2 divided doses for 6wks. |
|
Lialda | 1.2g | del-rel tabs | ≥18yrs: Remission induction: 2.4−4.8g once daily for up to 8wks. Maintenance: 2.4g once daily. <18yrs: Not established. |
|
Pentasa | 250mg, 500mg | controlled-rel caps | Adults: 1g four times daily for up to 8wks. Children: Not established. |
|
Rowasa | 4g/ 60mL |
enema | Adults: Treatment: 4g (60mL) daily at bedtime for 3−6wks. Retain enema for 8hrs. Children: Not recommended. |
|
olsalazine sodium | Dipentum | 250mg | caps | Adults: Maintenance: 500mg twice daily with meals. Children: Not recommended. |
sulfasalazine | Azulfidine | 500mg | scored tabs | Adults: Treatment: Initially 1−2g daily, increase gradually to 3−4g daily in equally divided doses after meals until symptoms controlled. Maintenance: 2g daily; max 4g/day. Children: <6yrs: not established. ≥6yrs: Treatment: Initially 40−60mg/kg daily in 3−6 doses. Maintenance: 30mg/kg daily in 4 doses. |
Azulfidine EN-tabs | 500mg | e-c tabs | ||
INTEGRIN RECEPTOR ANTAGONIST | ||||
vedolizumab | Entyvio | 300mg/ vial |
pwd for IV infusion after reconsti– tution |
≥18yrs: Give by IV infusion over 30mins. 300mg at Weeks 0, 2, and 6, then every 8wks thereafter. Discontinue if no therapeutic benefit by Week 14. <18yrs: Not established. |
JANUS KINASE INHIBITOR | ||||
tofacitinib | Xeljanz | 5mg, 10mg | tabs | Adults: 10mg twice daily for 8wks, then 5mg twice daily. May continue 10mg twice daily dose for up to max 16wks if needed; limit to those with loss of response. Discontinue after 16wks if inadequate response with 10mg twice daily. Children: Not established. |
STEROID | ||||
budesonide | Uceris | 9mg | ext-rel tabs | Adults: Remission induction: 9mg once daily in the AM for up to 8wks. Children: Not established. |
Uceris Rectal Foam | 2mg | emulsion | Adults: Apply 1 metered dose per rectum twice daily (AM & PM) for 2wks, then 1 metered dose once daily (PM) for 4wks. Children: Not established. |
|
TNF-ALPHA BLOCKER | ||||
adalimumab | Humira | 10mg/ 0.1mL, 10mg/ 0.2mL, 20mg/ 0.2mL, 20mg/ 0.4mL, 40mg/ 0.4mL, 40mg/ 0.8mL, 80mg/ 0.8mL |
soln for SC inj | ≥18yrs: Remission induction: 160mg (in 1 day or divided over 2 days) at Day 1, then 80mg at Day 15. Maintenance: At Day 29, start 40mg every other week. May continue aminosalicylates, corticosteroids, or immunomodulatory agents. Only continue if evidence of clinical remission by 8wks. <18yrs: Not recommended. |
golimumab | Simponi | 50mg/ 0.5mL, 100mg/ mL |
soln for SC inj | Adults: Remission induction: Initially 200mg by SC inj at Week 0, followed by 100mg at Week 2. Maintenance: 100mg every 4wks. Rotate inj sites. <18yrs: Not established. |
infliximab | Remicade | 100mg/ vial |
pwd for IV infusion after reconsti– tution and dilution |
Adults: Give by IV infusion over at least 2hrs. 5mg/kg at Weeks 0, 2, 6, then every 8wks. Heart failure: max 5mg/kg. Children: <6yrs: Not established. ≥6yrs: Same as adult dose. |
infliximab-abda | Renflexis | |||
infliximab- dyyb |
Inflectra | |||
NOTES | ||||
Not an inclusive list of medications, indications, or dosing details. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling. (Rev. 12/2019) |
Please login or register first to view this content.